Sight Sciences SGHT Revenue Breakdown

NASDAQ SGHT
$8.02 -0.06 (-0.74%)
At close: Sep 18, 2026 · 4:00 PM EDT
Annual revenue breakdowns for Sight Sciences, Inc., fiscal 2020 to 2025, as reported in its filings.
Annual history

Sight Sciences, Inc. Revenue by Segment

Years FY 2020–2025
Lines 2
FY 2025 Total $77.36M

Interventional Glaucoma was the largest of Sight Sciences, Inc.’s 2 reported lines in fiscal 2025, at $75.72M — 98% of $77.36M.

Sight Sciences, Inc. revenue by segment, fiscal 2020 to 2025
Segment FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Interventional Glaucoma $75.90M $75.72M
Interventional Dry Eye $3.96M $1.64M
Total $71.33M $81.06M $79.87M $77.36M
Totals include 2 discontinued lines from earlier reporting.

Sight Sciences, Inc. revenue by segment: what the figures show

In fiscal 2025, which ended December 31, 2025, the 2 segments Sight Sciences, Inc. reported in this breakdown added up to $77.36M. That was down 3.1% from $79.87M in fiscal 2024. Interventional Glaucoma was the largest segment, at $75.72M or 97.9% of the total, followed by Interventional Dry Eye ($1.64M, 2.1%).

Compared with fiscal 2024, every sizeable segment reported in both years shrank. Interventional Glaucoma held up best, down 0.2% to $75.72M, while Interventional Dry Eye fell the most, down 58.7% to $1.64M.

Interventional Glaucoma (fiscal 2024) and Interventional Dry Eye (fiscal 2024) were first reported as separate segments during this period. The table also keeps 2 segments that Sight Sciences, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2020 to 2025, as reported in Sight Sciences, Inc.'s annual filings.

Questions

Sight Sciences, Inc. Revenue Breakdown FAQ

How does Sight Sciences, Inc. make money?

Sight Sciences, Inc. (SGHT) breaks its revenue down by segment. In fiscal 2025, its largest segment was Interventional Glaucoma, with $75.72M or 97.9% of the total, followed by Interventional Dry Eye at $1.64M (2.1%).

What is Sight Sciences, Inc.'s largest segment?

Interventional Glaucoma was Sight Sciences, Inc.'s largest segment in fiscal 2025, with $75.72M in revenue, 97.9% of the $77.36M reported across its 2 segments.

Where does this revenue breakdown data come from?

Every figure is taken from Sight Sciences, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.

How far back does Sight Sciences, Inc.'s revenue breakdown go?

The breakdown by segment covers fiscal 2020 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.